Physician profile
Darnella Crowder
NPI 1437834025
$5,089.70
in general payments reported to CMS, 2019-2025
28 companies · $5,041 in 2025
The $5,041 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $48.98 · 2025: $5,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,067 · Education: $22.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,067.43 |
| Education | $22.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $751.42 | 2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $537.35 | 2025 | |
| Xeris Pharmaceuticals, INC. | $454.45 | 2025 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $414.46 | 2024-2025 | Korlym |
| Amgen INC. | $380.41 | 2025 | Tepezza, Evenity, Repatha |
| Radius Health, INC. | $322.66 | 2025 | Tymlos |
| Lilly USA, LLC | $292.74 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Insulet Corporation | $227.88 | 2025 | Omnipod, Omnipod |
| Ascendis Pharma Endocrinology INC | $205.43 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $196.28 | 2025 | Twiist |
| Medtronic, INC. | $190.05 | 2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $161.68 | 2025 | Isturisa |
| Mannkind Corporation | $145.72 | 2025 | |
| Cequr Corporation | $125.56 | 2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $111.18 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $91.43 | 2025 | |
| Madrigal Pharmaceuticals | $82.97 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.91 | 2025 | Jardiance |
| Abbott Laboratories | $51.56 | 2025 | Freestyle Libre 3 |
| Ionis Pharmaceuticals, INC. | $50.11 | 2025 | Tryngolza |
| Beta Bionics, INC. | $43.57 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novartis Pharmaceuticals Corporation | $37.32 | 2025 | |
| Antares Pharma, INC. | $35.04 | 2025 | Xyosted |
| Abbvie INC. | $31.28 | 2025 | |
| Dexcom, INC. | $29.39 | 2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $27.31 | 2025 | Nexletol |
| Amphastar Pharmaceuticals, INC. | $21.35 | 2025 | |
| Ibsa Pharma INC. | $17.19 | 2025 | Flector, Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darnella Crowder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.